TrialReader


Buxue Yimu Pills for Gynecological Iron-Deficiency Anemia

NCT03232554 — Phase 2, Unknown, 180 participants, Peking Union Medical College Hospital

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Clinical Observation of The Gynecological Iron-Deficiency Anemia Treated With Buxue Yimu Pills

RegistryNCT03232554, acronym BXYMIDA
StatusUnknown
PhasePhase 2
Study typeInterventional; randomized, parallel, masking: double, treatment
Enrollment180 (Estimated)
SponsorPeking Union Medical College Hospital (Other)
ConditionsIron-Deficiency Anemia
InterventionsBuxue Yimu Pills, Buxue Yimu Pills &Ferrous Sulfate, Ferrous Sulfate (Drug)
Datesstart 2017-06-01, primary completion 2018-12-31 (estimated), completion 2019-02-28 (estimated), first posted 2017-07-28, last updated 2018-02-13
Locations1 site in China

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Iron-Deficiency Anemia All trials of Buxue Yimu Pills All trials of Buxue Yimu Pills &Ferrous Sulfate

-Summary

This study evaluates Buxue Yimu Pills,Ferrous Sulfate and the addition of Buxue Yimu Pills to Ferrous Sulfate in the treatment of Iron-Deficiency Anemia in adults women. One third of participanta will receive Buxue Yimu Pills, one third of participanta will receive Buxue Yimu Pills, one third of participanta will receive Ferrous Sulfate,and the another third will receive Buxue Yimu Pills and Ferrous Sulfate in combination.

Expand all sections  ·  Collapse all

+Detailed description

Buxue Yimu Pills, Ferrous Sulfate each Improve anemia, but they do so by different machanisms. We generally treat patients with uncomplicated Iron Deficiency Anemia with oral iron due to the ease of administration,and Ferrous Sulfate is one of the most commonly used drugs.

Buxue Yimu Pills consists of multiple chinses herbs including Angelica Sinensis,Astragalus,Donkey-Hide Gelatin,Herba Leonuri,Citrus etc., which gains widespread application in the treatment after women's abortion or operations of uterine cavity. Based on the characteristics above, we try to explore its clinical application value in Gynecological Iron-Deficiency Anemia.

+Arms and interventions

ArmTypeInterventionsDescription
Buxue Yimu PillsExperimentalDrug: Buxue Yimu PillsBuxue Yimu Pill 12g pill by mouth, twice daily
Buxue Yimu Pills &Ferrous SulfateExperimentalDrug: Buxue Yimu Pills &Ferrous SulfateBuxue Yimu Pill 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
Ferrous SulfateActive comparatorDrug: Ferrous SulfateFerrous Sulfate 0.3g tablet by mouth, three times daily
  • Buxue Yimu Pills (Drug), also known as Buxue Yimu pellets: Buxue Yimu Pills 12g pill by mouth, twice daily.
  • Buxue Yimu Pills &Ferrous Sulfate (Drug), also known as Buxue Yimu pellets,Iron Sulfate: Buxue Yimu Pills 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
  • Ferrous Sulfate (Drug), also known as Iron Sulfate: Ferrous Sulfate 0.3g tablet by mouth, three times daily

+Outcome measures

Primary outcomes

  • Complete Blood Count [5 minutes]: Anemia Related Assessment

Secondary outcomes

  • The Short Form-36 Health Survey (Sf-36) [10 minutes]: Information about health
  • Hepatic Function [5 minutes]: Safety Monitoring
  • Renal Function [5 minutes]: Safety Monitoring
  • Blood Glucose [5 minutes]: Safety Monitoring
  • Electrolyte Semiconductor Junction [5 minutes]: Safety Monitoring
  • Electrocardiogram(ECG) [5 minutes]: Safety Monitoring
  • Iron Metabolism index [5 minutes]: Anemia Related Assessment

Other outcomes

  • Metabonomics Measurement [1hour]: Extensive and profound Information

+Eligibility

Sex: Female, ages: 18 Years to 50 Years

Inclusion Criteria:

* Subject is a female between the age of 18 and 50.
* Subject suffers from mild to moderate anemia with a hemoglobin between 80g/L and 110 g/L.
* Subject has definite gynecological etiological factors of iron deficiency
* Subject provides written informed consent.

Exclusion Criteria:

* Subject underwent chronic digestive tract inflammation,uncontrolled digestive or urinary system bleeding.
* Subject has other complications in addition to gynecological diseases leading to iron deficiency,such as hemorrhagic diseases of hematologic system,parasitic diseases like ancylostomiasis,chronic intravascular hemolysis,mechanical hemolysis like prosthetic valve,renal dysfunction and hemodialysis.
* Subject is pregnant or lactating.
* Subject has a severe systemic disease, such as cardiovascular system
* Subject has a history of malignancy or radiotherapy.
* Subject has undergone any Iron deficiency anemia treatment including Iron supplements or blood transfusion within 1month prior to randomization.
* Subject has mental disorder incapable of elementary cooperations.
* Subject has participated in other clinical researches of medicine within 1month prior to randomization.

+Locations (1)

FacilityCityCountryStatus
Lei LiBeijing, Beijing MunicipalityChinaRecruiting

+Publications

  • Results publication: Percy L, Mansour D, Fraser I. Iron deficiency and iron deficiency anaemia in women. Best Pract Res Clin Obstet Gynaecol. 2017 Apr;40:55-67. doi: 10.1016/j.bpobgyn.2016.09.007. Epub 2016 Oct 1. PMID 28029503
  • Results publication: Seid MH, Butcher AD, Chatwani A. Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia. Anemia. 2017;2017:9642027. doi: 10.1155/2017/9642027. Epub 2017 Apr 13. PMID 28487769
  • Results publication: Wang YF, Deng Y, Zhang SY, Liu D, Luo B, Wang X, Deng M, Ma RL, Sun AJ. Efficacy and Mechanism of Buxue Yimu Pills on Gynecological Anemia: A Combination of Clinical and Network Pharmacology Study. Chin J Integr Med. 2022 Dec;28(12):1072-1080. doi: 10.1007/s11655-021-3296-7. Epub 2021 Jul 9. PMID 34241801

+Study documents

+Investigators

  • Aijun AJ Sun, MD, Principal investigator, Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences

My Notes